Chinese health company (301408.SZ) plans to acquire equity of three pharmaceutical chain companies in Fujian and Zhejiang, promoting the company's pharmaceutical retail business.

The Zhifinancial APP reported that Huaren Health (301408.SZ) has announced plans to continue advancing the company's pharmaceutical retail business development strategy of "deep cultivation in Anhui, focusing on East China, and radiating surrounding areas". In order to enhance the company's market share and brand influence in East China, the company intends to purchase 46.01% of Yangzu Huimin's equity held by Minzhe Hui for RMB 133 million, and purchase 46.01% of Haihua Medicine's equity held by Minzhe Hui for RMB 125 million, as well as purchase 70.01% of Tonglu Yishengtang's equity held by Minzhe Hui for RMB 68.25975 million.